The Biologics Contract Development and Manufacturing Organization (CDMO) Market Report offers a detailed assessment of the market scenario, including the size, trends, and competitive landscape shaping the industry. It highlights critical insights on product innovations, regulatory influences, and strategic developments by leading players.

This research focuses on how technological disruptions and consumer trends are redefining business operations. It also examines emerging applications and regional opportunities that contribute to the market’s long-term growth trajectory.

Biologics Contract Development and Manufacturing Organization (CDMO) Market Size

• The global biologics contract development and manufacturing organization (CDMO) market size was valued at USD 16.61 billion in 2024 and is expected to reach USD 38.27 billion by 2032, at a CAGR of 11.00% during the forecast period
• The market growth is largely fueled by the growing adoption and technological progress within biologic therapies and advanced manufacturing technologies, leading to increased outsourcing by pharmaceutical and biotechnology companies to specialized Biologics Contract Development and Manufacturing Organizations (CDMOs). The complexity of biologics production, including monoclonal antibodies, recombinant proteins, and cell and gene therapies, has driven demand for CDMOs with deep technical expertise and regulatory compliance capabilities
• Furthermore, rising demand for cost-effective, scalable, and flexible manufacturing solutions is establishing CDMOs as strategic partners of choice for both large pharma and emerging biotech firms. These converging factors are accelerating the uptake of Biologics CDMO solutions, thereby significantly boosting the industry's growth. CDMOs offering integrated services—from early-stage development and process optimization to clinical and commercial-scale manufacturing—are particularly well-positioned to benefit from the growing biologics pipeline across therapeutic areas such as oncology, autoimmune diseases, and rare disorders

Explore the full analysis: https://www.databridgemarketresearch.com/reports/global-biologics-contract-development-and-manufacturing-organization-cdmo-market

Biologics Contract Development and Manufacturing Organization (CDMO) Market Scope

The market is segmented on the basis of product type, service type, and end-users.

• By Product Type

On the basis of product type, the biologics contract development and manufacturing organization (CDMO) market is segmented into gene products, vaccines, stem cells, monoclonal antibodies, and others. The monoclonal antibodies segment dominated the largest market revenue share of 41.6% in 2024, driven by their widespread use in oncology, autoimmune diseases, and infectious disorders. The increasing approvals of monoclonal antibody therapies and the rising number of pipeline candidates are significantly driving this segment.

The gene products segment is projected to witness the fastest CAGR of 18.2% from 2025 to 2032, attributed to growing demand for gene therapies in rare and genetic diseases and advancements in vector-based delivery platforms.

• By Service Type

On the basis of service type, the biologics contract development and manufacturing organization (CDMO) market is segmented into manufacturing, research and development, clinical trials, and others. The manufacturing segment held the largest market revenue share of 48.9% in 2024, due to the increasing outsourcing of commercial-scale production and the complexity of biologics requiring specialized infrastructure.

The clinical trials segment is expected to witness the fastest growth rate of 16.5% from 2025 to 2032, driven by the rising number of biologic drug candidates entering clinical evaluation and the need for end-to-end CDMO support services.

• By End-Users

On the basis of end-users, the biologics contract development and manufacturing organization (CDMO) market is segmented into biotechnology companies, biopharmaceutical companies, and others. The biopharmaceutical companies segment accounted for the largest market share of 55.3% in 2024, driven by increasing partnerships and long-term outsourcing agreements with CDMOs to accelerate biologics development pipelines.

The biotechnology companies segment is expected to register the fastest CAGR of 17.4% during the forecast period, owing to the surge in startup activity, venture capital funding, and demand for cost-effective external development capabilities.

The biologics contract development and manufacturing organization (CDMO) industry is primarily led by well-established companies, including:

• Boehringer Ingelheim Group (Germany)
• Wuxi Biologics (China)
• Samsung Biologics (South Korea)
• Lonza Group (Switzerland)
• Fujifilm Diosynth Biotechnologies USA Inc. (U.S.)
• Toyobo Co. Limited (Japan)
• Parexel International Corporation (U.S.)
• Icon PLC (Ireland)
• Binex Co. Limited (South Korea)
• JRS Pharma (Germany)
• Rentschler Biotechnologies (Germany)
• AGC Biologics (U.S.)
• Catalent Inc. (U.S.)

Latest Developments in Global Biologics Contract Development and Manufacturing Organization (CDMO) Market

• In July 2025, Thermo Fisher Scientific announced the acquisition of Sanofi’s biologics fill–finish facility in Ridgefield, New Jersey, aimed at expanding its biologics manufacturing capabilities in the U.S. This acquisition strengthens Thermo Fisher’s long-term partnership with Sanofi and increases capacity to meet rising demand in biologics development and production
• In March 2025, Zydus Lifesciences entered the U.S. biologics CDMO market through the acquisition of two manufacturing facilities in California (Emeryville & Berkeley) from a global biotech firm. The USD 75 million deal marks a significant strategic expansion, allowing Zydus to scale its biologics and biosimilars portfolio in North America
• In March 2025, Syngene International acquired its first U.S.-based biologics manufacturing facility in Baltimore from Emergent BioSolutions for USD 36.5 million. The acquisition is expected to boost Syngene’s biologics capacity and support clients seeking commercial manufacturing for complex biologics and injectables
• In February 2025, Lonza Group finalized the acquisition of Roche’s large-scale biologics manufacturing site in Vacaville, California, for USD 1.2 billion. The deal adds 330,000 liters of capacity and will be followed by a CHF 500 million investment to upgrade and expand the facility to meet future commercial demand
• In January 2025, Bora Biologics announced the expansion of its San Diego biologics CDMO facility. The company is adding GMP suites and over 8,000 square feet of cleanroom space to support upstream and downstream biologics processing. This move aligns with growing client demand for full-service biologics development

Key Report Highlights
Comprehensive Market Size & Forecast Data
Trend and Technology Assessment
Competitor Analysis & Strategic Insights
Segmentation by Type and Application
Consumer and End-User Insights
Regional and Outlook

Report Structure
Introduction
Market Dynamics and Scope
Segmentation and Forecasts
Competitive Environment
Opportunities and Key Recommendations
Regional Analysis

Browse More Reports:
Global Beer Cans Market
Global Bentonite Market
Global Betanin Food Color Market
Global Biliary Atresia Treatment Market
Global Billiard Cues Market
Global Bioactive Fillings Market
Global Bio Based Polytrimethylene Terephthalate (PTT) Market
Global Biofuel Enzyme Market
Global Biofuel Lubricity Improvers Market
Global Biological Dural Repair Market
Global Biopolymer Coatings Market
Global Birth Defects Market
Global Bitcoin Payments Ecosystem Market
Global Bluetooth Hearing Aids Market
Global Body Butter Market
Global Body Shaper Market
Global Bone Healing Implants Market
Global Bone Metastasis Market
Global Bone Spur Market
Global Biaxially-Oriented Polyethylene Terephthalate (BOPET) Packaging Films Market

About Data Bridge Market Research:
An absolute way to forecast what the future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC: +653 1251 975
Email: corporatesales@databridgemarketresearch.com